Saturday 17 October 2026
Export CHRS’s income statement to Excel — free account
Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
1.00
0.07
−6.54%
Follow CHRS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
1.23 | 0.97 | 1.01 | 0.00 |
P/S ratio |
5.13 | 3.94 | 4.92 | 4.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.11) | (8.44) | (3.98) | (3.49) | |
P/B ratio |
2.17 | 2.73 | 2.93 | 3.56 | |
Price to Tangible BV |
4.98 | 11.26 | 6.98 | 13.68 | |
EV/Sales |
5.68 | 4.89 | 5.88 | 6.35 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.34) | (1.49) | (1.62) | (1.74) | |
EV/FCF |
(2.31) | (1.48) | (1.61) | (1.73) | |
Quick Ratio |
1.19 | 1.36 | 1.43 | 1.58 | |
Current Ratio |
1.24 | 1.47 | 1.56 | 1.77 | |
Net Debt/EBITDA |
3.57 | 3.00 | 3.68 | 2.16 | |
Debt/Assets |
7.16% | 14.34% | 13.96% | 19.48% | |
Debt/Equity |
0.42 | 0.61 | 0.47 | 0.61 | |
Asset Turnover |
0.07 | 0.12 | 0.15 | 0.16 | |
Operating CF/Net income |
1.30 | 0.52 | 1.51 | 3.01 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(19.07) | (20.40) | (16.54) | (13.92) | |
Research and Development Expense of Revenue |
235.52% | 242.97% | 175.00% | 149.87% | |
Selling, General and Administrative Expense of Revenue |
215.46% | 185.20% | 187.68% | 146.46% | |
Intangible Assets out of Total Assets |
0.10 | 0.18 | 0.17 | 0.24 | |
Share Based Compensation of Revenue |
29.29% | 21.84% | 19.37% | 18.05% | |
Graham Net Nets |
0.17 | 0.06 | 0.08 | 0.02 | |
Graham Number |
4.75 | 4.14 | 4.65 | 0.00 | |
Earnings Yield |
81.10% | 102.82% | 98.82% | (73.57%) | |
Free Cash Flow Yield |
(47.81%) | (83.84%) | (74.41%) | (86.26%) | |
Revenue per Share |
0.10 | 0.11 | 0.09 | 0.09 | |
Operating CF per Share |
(0.40) | (0.17) | (0.42) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | (0.17) | (0.42) | (0.40) | |
Cash per Share |
1.65 | 1.47 | 1.22 | 0.68 | |
Shareholders Equity per Share |
0.76 | 0.52 | 0.58 | 0.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.76 | 0.52 | 0.58 | 0.39 | |
Free Cash Flow |
(46.34) | (19.72) | (57.89) | (62.09) | |
Working Capital |
88.66 | 66.32 | 73.70 | 58.28 | |
Net Current Asset Value |
32.21 | 9.38 | 18.64 | 3.44 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
224.65 | 70.38 | 42.47 | 66.95 | |
Average Payables |
23.39 | 19.19 | 26.20 | 25.40 | |
Average Inventory |
24.84 | 3.69 | 4.17 | 5.09 | |
Average Assets |
510.76 | 353.44 | 318.54 | 315.32 | |
Average Common Equity |
(0.10) | (35.49) | (52.42) | 90.33 |
Columns are period end dates